[go: up one dir, main page]

WO2003041637A3 - Compositions lyophilisees d'anticorps monoclonaux - Google Patents

Compositions lyophilisees d'anticorps monoclonaux Download PDF

Info

Publication number
WO2003041637A3
WO2003041637A3 PCT/US2002/033272 US0233272W WO03041637A3 WO 2003041637 A3 WO2003041637 A3 WO 2003041637A3 US 0233272 W US0233272 W US 0233272W WO 03041637 A3 WO03041637 A3 WO 03041637A3
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibody
lyophilized
antibody compositions
lyophilized monoclonal
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/033272
Other languages
English (en)
Other versions
WO2003041637A2 (fr
Inventor
Tracy Chen
Glen Tolman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Priority to MXPA04004459A priority Critical patent/MXPA04004459A/es
Priority to EP02773798A priority patent/EP1455822A4/fr
Priority to JP2003543524A priority patent/JP2005508992A/ja
Priority to CA002466641A priority patent/CA2466641A1/fr
Publication of WO2003041637A2 publication Critical patent/WO2003041637A2/fr
Publication of WO2003041637A3 publication Critical patent/WO2003041637A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition pharmaceutique solide améliorée comprenant une composition lyophilisée d'anticorps monoclonaux qui manifeste une meilleure stabilité sous forme séchée et a une température de transition vitreuse élevée. Selon l'invention, une composition lyophilisée d'anticorps monoclonaux comprend un anticorps monoclonal thérapeutiquement actif ou un fragment de celui-ci, mélangé à un excipient stabilisateur comprenant une combinaison de disaccharide et d'amidon hydroxyéthylique. De préférence, l'anticorps monoclonal est l'abciximab.
PCT/US2002/033272 2001-11-09 2002-10-18 Compositions lyophilisees d'anticorps monoclonaux Ceased WO2003041637A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
MXPA04004459A MXPA04004459A (es) 2001-11-09 2002-10-18 Composiciones liofilizadas de anticuerpo monoclonal.
EP02773798A EP1455822A4 (fr) 2001-11-09 2002-10-18 Compositions lyophilisees d'anticorps monoclonaux
JP2003543524A JP2005508992A (ja) 2001-11-09 2002-10-18 凍結乾燥されたモノクローナル抗体組成物
CA002466641A CA2466641A1 (fr) 2001-11-09 2002-10-18 Compositions lyophilisees d'anticorps monoclonaux

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34206301P 2001-11-09 2001-11-09
US60/342,063 2001-11-09

Publications (2)

Publication Number Publication Date
WO2003041637A2 WO2003041637A2 (fr) 2003-05-22
WO2003041637A3 true WO2003041637A3 (fr) 2004-01-22

Family

ID=23340162

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/033272 Ceased WO2003041637A2 (fr) 2001-11-09 2002-10-18 Compositions lyophilisees d'anticorps monoclonaux

Country Status (7)

Country Link
EP (1) EP1455822A4 (fr)
JP (1) JP2005508992A (fr)
AR (1) AR037304A1 (fr)
CA (1) CA2466641A1 (fr)
MX (1) MXPA04004459A (fr)
TW (1) TW200303213A (fr)
WO (1) WO2003041637A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982080B2 (en) 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
CA2744510A1 (fr) * 2008-12-09 2010-06-17 F.Hoffmann-La Roche Ag Procede d'obtention d'une solution d'anticorps exempte d'excipient
WO2012028683A1 (fr) 2010-09-02 2012-03-08 Novartis Ag Système de gel d'anticorps pour administration de médicament prolongée
CA3116725C (fr) 2010-11-05 2023-10-24 Novartis Ag Secukinumab a utiliser dans le traitement de la polyarthrite psoriasique
HUE059339T2 (hu) 2017-09-15 2022-11-28 Amgen Inc Eljárás terápiás fehérje liofilizált gyógyászati kiszerelésére

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891319A (en) * 1985-07-09 1990-01-02 Quadrant Bioresources Limited Protection of proteins and the like
WO1996040077A2 (fr) * 1995-06-07 1996-12-19 Quadrant Holdings Cambridge Limited Procedes permettant d'incorporer de façon stable des substances dans des matrices seches de verre mousse, et compositions ainsi obtenues
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5762961A (en) * 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
US5955448A (en) * 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
US20020136719A1 (en) * 2000-12-28 2002-09-26 Bhami Shenoy Crystals of whole antibodies and fragments thereof and methods for making and using them

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000807A1 (fr) * 1991-07-03 1993-01-21 Cryolife, Inc. Procede de stabilisation de biomateriaux
WO1993014191A1 (fr) * 1992-01-21 1993-07-22 Cryopharm Corporation Procede de congelation de cellules et de matieres analogues a des cellules

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891319A (en) * 1985-07-09 1990-01-02 Quadrant Bioresources Limited Protection of proteins and the like
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US6313102B1 (en) * 1994-04-13 2001-11-06 Quardrant Holdings Cambridge, Ltd. Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
US5955448A (en) * 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
WO1996040077A2 (fr) * 1995-06-07 1996-12-19 Quadrant Holdings Cambridge Limited Procedes permettant d'incorporer de façon stable des substances dans des matrices seches de verre mousse, et compositions ainsi obtenues
US5762961A (en) * 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
US20020136719A1 (en) * 2000-12-28 2002-09-26 Bhami Shenoy Crystals of whole antibodies and fragments thereof and methods for making and using them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1455822A4 *

Also Published As

Publication number Publication date
AR037304A1 (es) 2004-11-03
JP2005508992A (ja) 2005-04-07
TW200303213A (en) 2003-09-01
MXPA04004459A (es) 2005-05-16
WO2003041637A2 (fr) 2003-05-22
EP1455822A2 (fr) 2004-09-15
EP1455822A4 (fr) 2004-12-29
CA2466641A1 (fr) 2003-05-22

Similar Documents

Publication Publication Date Title
WO2003054007A3 (fr) Antigenes de streptococcus
WO2002092797A3 (fr) Variant d'alpha-amylases ayant des proprietes modifiees
WO2005032582A3 (fr) Compositions immunogènes pour streptococcus pyogenes
WO2003011878A3 (fr) Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps
AU2001236073A1 (en) Gene recombinant antibody and its fragment
WO2001058412A3 (fr) Extraits de residus de la production de vin
WO2005108561A3 (fr) Enzyme recombinante presentant une sensibilite modifiee a la reaction
AU2001284479A1 (en) Ceramic/metal composite article, composite structure for transporting oxide ion, and composite article having sealing property
WO2003049581A3 (fr) Structures a base de bourres plissees pour remplissage et isolation
AU2002232819A1 (en) Methods for the production of multimeric proteins, and related compositions
AU2001297896A1 (en) Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
AU3281902A (en) Methods for the production of multimeric proteins, and related compositions
AU2101601A (en) Ceramic compositions, physical vapor deposition targets and methods of forming ceramic compositions
WO2003041637A3 (fr) Compositions lyophilisees d'anticorps monoclonaux
BR0015630B1 (pt) material refratÁrio isolante, artigo, e, composiÇço aquosa para a fabricaÇço de um material refratÁrio isolante.
WO2001081380A3 (fr) Proteine pneumococcique immunogenique et ses compositions de vaccins
AU2002366260A1 (en) Structured surfaces having elevations and depressions, method for producing surfaces of this type and the use thereof
BR0213704B1 (pt) composição refratária não conformada, destinada especialmente à construção de soleiras de um forno para fabricação de vidro e produto refratário.
AU2000266451A1 (en) Toughened, high-modulus polyacetals
AU2001273405A1 (en) Down syndrome critical region 1-like 1 proteins
WO2003015689A3 (fr) Composition pharmaceutique de prevention et/ou de traitement de maladies virales
WO2002028889A3 (fr) Antigenes d'haemophilus influenzae et fragments d'adn correspondants
AU3054001A (en) Dielectric porcelain composition and dielectric resonator using the same
AU3922900A (en) Use of (valeriana) for the treatment of restless leg syndrome and related disorders
WO2001088137A3 (fr) Proteines du type proteine adaptatrice myd88

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002337895

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/004459

Country of ref document: MX

Ref document number: 2003543524

Country of ref document: JP

Ref document number: 2466641

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002773798

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002773798

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002773798

Country of ref document: EP